

Center for Vaccine
Ethics and Policy



Vaccines and Global Health: The Week in Review
20 April 2024 :: Issue 747
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Milestones, Perspectives



OCV

WHO prequalifies new oral simplified vaccine for cholera

18 April 2024 *Departmental news*

A new oral vaccine for cholera has received prequalification by the World Health Organization (WHO) on 12 April. **The inactivated oral vaccine Euvichol-S has a similar efficacy to existing vaccines but a simplified formulation, allowing opportunities to rapidly increase production capacity.**

“The new vaccine is the third product of the same family of vaccines we have for cholera in our WHO prequalification list,” said Dr Rogerio Gaspar, Director of the WHO Department for Regulation and Prequalification. **“The new prequalification is hoped to enable a rapid increase in production and supply which many communities battling with cholera outbreaks urgently need.”**

WHO prequalification list already includes Euvichol and Euvichol-Plus inactivated oral cholera vaccines produced by EuBiologicals Co., Ltd, Republic of Korea, which also produces the new vaccine Euvichol-S.

Vaccines provide the fastest intervention to prevent, limit and control cholera outbreaks but supplies have been at the lowest point amidst countries facing dire shortcomings in other areas of cholera prevention and management such as safe water, hygiene and sanitation.

There were 473 000 cholera cases reported to WHO in 2022 -- double the number from 2021. Further increase of cases by 700 000 was estimated for 2023. Currently, 23 countries are reporting cholera outbreaks with most severe impacts seen in the Comoros, Democratic Republic of the Congo, Ethiopia, Mozambique, Somalia, Zambia and Zimbabwe.



EuBiologicals' simplified OCV achieves WHO PQ

:: Euvichol-S, developed jointly by EuBiologicals and IVI, improves productivity by approximately 40% over Euvichol-Plus®

:: Production and supply of Euvichol-S expected to help address cholera vaccine shortages

April 15, 2024, SEOUL, Republic of Korea – EuBiologicals and the International Vaccine Institute (IVI) announced that Euvichol-S, an improved oral cholera vaccine (OCV) developed jointly by EuBiologicals and IVI, has achieved World Health Organization prequalification (PQ). **Euvichol-S is a new OCV that has improved productivity by about 40 percent over the existing Euvichol-Plus® by modifying the formulation and manufacturing method of the original vaccine material.**

In May last year, EuBiologicals submitted a PQ application to WHO with technical support from IVI after a field inspection of its GMP facilities by the Korean Ministry of Food and Drug Safety on behalf

of WHO. The new vaccine received an export license from KMFDS in December before winning the WHO seal of approval in about 10 months after application.

EuBiologics will now be able to produce and supply three oral cholera vaccines, including Euvichol® (in glass vials) and Euvichol-Plus®. There is a significant global shortage of vaccine for cholera prevention as reported recently by The New York Times, and the expected supply of Euvichol-S to UN agencies is expected to ease this supply shortage.

Euvichol-S was developed through technological collaboration between EuBiologics and Dr. Julia Lynch's team at IVI, and its efficacy was demonstrated in a Phase 3 comparative clinical trial in Nepal last year. **The development of the vaccine was funded by the Bill & Melinda Gates Foundation,** and the vaccine will be produced and distributed by EuBiologics. After the scale-up process, Euvichol-S will be mass produced in GMP facilities at the company's Chuncheon Plant 1 and Plant 2 in the Republic of Korea beginning in the second quarter.

Dr. Julia Lynch, Director of IVI's Cholera Program, said, "The addition of Euvichol-S to global health market will contribute to easing the shortage of OCV supply amid a dire global cholera situation. IVI will continue efforts to enhance the availability of OCV worldwide and develop new and improved vaccines that are equally safe, effective, and affordable."

.....

[Gavi and UNICEF welcome approval of new oral cholera vaccine](#)

GENEVA/NEW YORK, 18 April 2024 – Gavi, the Vaccine Alliance and UNICEF welcome the news that a new oral cholera vaccine (OCV), Euvichol-S, has now received WHO prequalification and can be made available to countries around the world. The prequalification of this new product will help EuBiologics, the manufacturer, produce more volumes of vaccine, faster, and at a lower cost – a key step to expanding supply amidst the on-going acute global upsurge of cholera outbreaks.

Today's approval will help increase the overall supply of oral cholera vaccines available in 2024, with **approximately 50 million doses now forecasted to be available to the global stockpile this year, compared to 38 million in 2023.** Euvichol-S is an important product innovation: a simplified formulation of Euvichol-Plus that reduces the number of vaccine components – delivering a vaccine that studies have shown remains equally effective against key cholera serogroups while lowering production cost and complexity – thus allowing for larger volumes to be produced faster...

.....

Cholera

[WHO- Multi-country outbreak of cholera, External situation report #13 - 17 April 2024](#)

Overview

Since the beginning of 2023, a cumulative total 824 479 cholera cases and 5900 deaths were reported from 31 countries across five WHO regions, as of 31 March 2024, with the Eastern Mediterranean region recording the highest numbers, followed by the African Region, the Region of the Americas, the South-East Asia Region, the Western Pacific Region. No outbreaks were reported in the European Region during this time.

The cholera response continues to be affected by a critical shortage of Oral Cholera Vaccines (OCV). Since January 2023, OCV requests have surged, with 79 million doses requested by 14 countries, double the 40 million doses available during this period. The global stockpile of vaccines was

depleted until the beginning of March. As of 15 April, the stockpile has 2.3 million doses, which is below the global stockpile target of five million doses.

Table 1. Cholera cases and deaths reported from WHO regions, as of 31 March 2024*

WHO Region	Country, area, territory	1 January to 31 December 2023				1 January to 31 March 2024			
		Cases	Deaths	Cases per 100 000	CFR (%)	Cases	Deaths	Cases per 100 000	CFR (%)
African Region	Burundi	1 348	9	10	0.7	109	0	1	0
	Cameroon	6 450	209	23	3.2	75	0	0	0
	Comoros [#]	-	-	-	-	678	17	82	2.5
	Congo [§]	21	5	0	23.8	-	-	-	-
	Democratic Republic of the Congo	51 970	437	43	0.8	10 754	186	9	1.7
	Eswatini [§]	2	0	0	0	-	-	-	-
	Ethiopia	30 463	413	41	1.4	9 429	111	13	1.2
	Kenya	8 926	145	19	1.6	289	1	1	0.3
	Malawi	41 219	1 179	235	2.9	205	3	1	1.5
	Mozambique	39 908	156	138	0.4	6 346	12	22	0.2
	Nigeria	3 683	128	2	3.5	318	4	0	1.3
	South Africa	1 291	47	2	3.6	6	0	0	0
	South Sudan [§]	348	1	3	0.3	-	-	-	-
	Togo [§]	1	0	0	0	-	-	-	-
	Uganda	80	10	0	12.5	32	1	0	3.1
	United Republic of Tanzania	1 068	23	2	2.2	2 043	28	3	1.4
Zambia	4 095	117	21	2.9	19 319	621	99	3.2	
Zimbabwe	14 517	320	96	2.2	16 126	323	106	2	
Eastern Mediterranean Region	Afghanistan ^{**}	222 249	101	679	0	24 553	13	75	0.1
	Iraq [§]	1 376	7	3	0.5	-	-	-	-
	Lebanon [§]	2 386	0	43	0	-	-	-	-
	Pakistan ^{***}	145	0	0	0	3 182	0	1	0
	Somalia	18 304	46	112	0.3	6 605	72	40	1.1
	Sudan	8 843	246	21	2.8	2 252	62	5	2.8
	Syrian Arab Republic	180 288	7	815	0	9 718	0	44	0
	Yemen [#]	3 804	14	11	0.4	875	3	3	0.3
Region of the Americas	Dominican Republic [§]	149	0	1	0	-	-	-	-
	Haiti	56 355	779	486	1.4	2 672	13	23	0.5
South-East Asia Region	Bangladesh	158	0	18	0	3	0	0	0
	India	5 436	14	0	0.3	269	1	0	0.4
Western Pacific Region	Philippines [§]	3 756	19	3	0.5	-	-	-	-

* Case and death numbers presented are not directly comparable due to differences in case definitions, reporting systems, and general underreporting. All data are subject to verification and change due to data availability and accessibility. Respective figures and numbers will be updated as more information becomes available. The data in Table 1 includes suspected, rapid diagnostic test (RDT) positive, and culture-confirmed cholera cases. No cholera cases of local transmission have been reported in the European Region.

** Afghanistan reports AWD through the sentinel site surveillance system.

*** Refers to the laboratory-confirmed cases only in 2023. Since January 2024, the number of suspected cholera and AWD cases are included based on the available [Public Health Bulletin published by the National Institute of Health](#).

[§] Countries did not report cholera cases from 1 January to 31 March 2024.

[#] Comoros did not report cholera cases in 2023.

^{*} Epidemiological situation of diseases in free areas of Yemen: [Link](#)

WHO classified the global resurgence of cholera as a grade 3 emergency in January 2023, its highest internal level for emergencies. Based on the number of outbreaks and their geographic expansion, alongside the shortage of vaccines and other resources, WHO re-assessed the risk at the global level as very high and the event remains classified as a grade 3 emergency.

We would like to have your response for the following end-user survey: *External situation report: Multi-country outbreak of cholera*: <https://extranet.who.int/dataformv3/index.php/458396?lang=en>
Cholera upsurge (2021-present): <https://www.who.int/emergencies/situations/cholera-upsurge/>

.....

Nature Medicine

Volume 30 Issue 4, April 2024

<https://www.nature.com/nm/volumes/30/issues/4>

Articles

[Enhanced cholera surveillance to improve vaccination campaign efficiency](#)

A modeling study of 35 cholera-affected countries in Africa showed that introducing cholera surveillance could improve the effectiveness and cost-effectiveness of preventive cholera vaccination campaigns.

Hanmeng Xu, Kaiyue Zou, Elizabeth C. Lee

Abstract

Systematic testing for *Vibrio cholerae* O1 is rare, which means that the world's limited supply of oral cholera vaccines (OCVs) may not be delivered to areas with the highest true cholera burden. Here we used a phenomenological model with subnational geographic targeting and fine-scale vaccine effects to model how expanding *V. cholerae* testing affected impact and cost-effectiveness for preventive vaccination campaigns across different bacteriological confirmation and vaccine targeting assumptions in 35 African countries. Systematic testing followed by OCV targeting based on confirmed cholera yielded higher efficiency and cost-effectiveness and slightly fewer averted cases than status quo scenarios targeting suspected cholera. Targeting vaccine to populations with an annual incidence rate greater than 10 per 10,000, the testing scenario averted 10.8 (95% prediction interval (PI) 9.4–12.6) cases per 1,000 fully vaccinated persons while the status quo scenario averted 6.9 (95% PI 6.0–7.8) cases per 1,000 fully vaccinated persons. In the testing scenario, testing costs increased by US\$31 (95% PI 25–39) while vaccination costs reduced by US\$248 (95% PI 176–326) per averted case compared to the status quo. Introduction of systematic testing into cholera surveillance could improve efficiency and reach of global OCV supply for preventive vaccination.

.....

.....

NASEM Consensus Study – COVID-19 Vaccines

[Evidence Review of the Adverse Effects of COVID-19 Vaccination and Intramuscular Vaccine Administration](#)

Consensus Study Report (2024)

Contributor(s): National Academies of Sciences, Engineering, and Medicine; [Health and Medicine Division](#); [Board on Population Health and Public Health Practice](#); [Committee to Review Relevant Literature Regarding Adverse Events Associated with Vaccines](#); Anne R. Bass, Kathleen Stratton, Ogan K. Kumova, and Dara Rosenberg, Editors

PDF: <https://nap.nationalacademies.org/download/27746>

Abstract

Vaccines are a public health success story, as they have prevented or lessened the effects of many infectious diseases. To address concerns around potential vaccine injuries, the Health Resources and Services Administration (HRSA) administers the Vaccine Injury Compensation Program (VICP) and the Countermeasures Injury Compensation Program (CICP), which provide compensation to those who assert that they were injured by routine vaccines or medical countermeasures, respectively. The National Academies of Sciences, Engineering, and Medicine have contributed to the scientific basis for VICP compensation decisions for decades.

HRSA asked the National Academies to convene an expert committee to review the epidemiological, clinical, and biological evidence about the relationship between COVID-19 vaccines and specific adverse events, as well as intramuscular administration of vaccines and shoulder injuries. This report outlines the committee findings and conclusions.



[New Comprehensive Review Examines Potential Harms of COVID-19 Vaccination and Intramuscular Vaccination](#)

NASEM *News Release* | April 16, 2024

WASHINGTON — A [new report](#) from the National Academies of Sciences, Engineering, and Medicine reviews evidence for 19 potential harms of the COVID-19 vaccines, and for nine potential shoulder injuries from intramuscular administration of vaccines more broadly. The committee that conducted **the review identified sufficient evidence to draw 20 conclusions about whether these vaccines could cause specific harms, and drew 65 conclusions where it did not find enough evidence to establish, accept, or reject a causal relationship.**

The Health Resources and Services Administration requested that the National Academies convene a committee to review the evidence regarding specific potential harms related to the COVID-19 vaccines used in the United States, for which HRSA had received claims for compensation under its Countermeasures Injury Compensation Program (CICP).

As part of “Operation Warp Speed,” a rapid response by the federal government to speed vaccine development during the COVID-19 pandemic, four vaccines were developed and authorized for emergency use in the U.S., with some now fully approved by the Food and Drug Administration. COVID-19 vaccines are estimated to have prevented 14.4 million deaths worldwide in the first year they were available.

COVID-19 Vaccines and Possible Harms

The report concludes that two messenger ribonucleic acid (mRNA) vaccines, manufactured by Pfizer-BioNTech and Moderna, can cause myocarditis — inflammation of the heart muscle. Evidence suggests the two mRNA vaccines do not cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with thrombocytopenia syndrome (TTS), or myocardial infarction (heart attack). Evidence also suggests the Pfizer-BioNTech vaccine does not cause ischemic stroke.

Although there are a limited number of published studies on the Janssen vaccine, reflecting its limited use in the U.S., evidence suggests this vaccine may cause TTS and Guillain-Barré syndrome. The report says that for all conclusions that do not establish a causal link, future studies that estimate effects more precisely or that better minimize bias and confounding variables could lead to a different finding.

“Despite a large body of evidence from extraordinary efforts by investigators around the world, our committee found that in many cases, if not most, evidence was insufficient to accept or reject causality for a particular potential harm from a specific COVID-19 vaccine,” said committee vice chair Anne Bass, professor of clinical medicine, Weill Cornell

Medicine, and a rheumatologist at the Hospital for Special Surgery and New York Presbyterian Hospital. "In other cases, we did find sufficient evidence to favor rejection, favor acceptance, or establish causality. It is important to note, however, that identifying a harm does not mean that it occurs frequently. Harms associated with vaccines are rare."

Shoulder Injuries and Possible Harms

HRSA also requested that the committee review the evidence regarding any vaccine administration — not specifically COVID-19 vaccines — and shoulder injuries, to help its National Vaccine Injury Compensation Program (VICP) better understand whether vaccination can cause very specific types of shoulder injuries or a more general syndrome that it designated as "Shoulder Injuries Related to Vaccine Administration." The report says that evidence shows vaccination may cause four specific shoulder injuries: acute subacromial/subdeltoid bursitis caused by direct injection of a vaccine into the bursa; acute rotator cuff tendinopathy caused by direct injection into or adjacent to a tendon; bone injury caused by direct injection into or adjacent to bone; and axial or radial nerve injury due to direct injection into or adjacent to the nerve. In addition, evidence suggests that intramuscular vaccine administration does not cause chronic rotator cuff disease.

Evidence in Children

Because potential vaccine-associated harms may differ in children and adults, **the committee conducted an in-depth review of literature on adverse events related to COVID-19 vaccines in children under 18, and found insufficient evidence to make conclusions specific to children.** At the time of the committee's review, data on children were only available for the Pfizer-BioNTech and Moderna vaccines, due to later authorization of COVID-19 vaccines for emergency use in children, and decreased uptake of COVID-19 vaccines in children, particularly those younger than 11. Ongoing and future pharmacovigilance and epidemiology studies should produce more definitive data on the risk and relative incidence of harms of COVID-19 vaccines in children.

About This Study

The report says all conclusions must be assessed in the context of the established harms of COVID-19 infection and the well-documented benefits of COVID-19 vaccines in preventing infection. The committee was not tasked with estimating the magnitude or strength of associations between vaccinations and outcomes, and did not offer conclusions regarding specific patient cases or whether VICP or CACP should award compensation in individual cases or in general.

"Given that the studies we reviewed were performed shortly after vaccines were available, the information in this report is a snapshot in time, and new vaccines will be developed and more research conducted," said George Isham, senior fellow, HealthPartners Institute, and chair of the committee that wrote the report. "For example, the evidence does not address the real-world use of the COVID-19 vaccines in which many individuals received a 'mix and match' sequence of them. Many people vaccinated for COVID-19 also received other vaccines, such as influenza, simultaneously."

The study — undertaken by the Committee to Review Relevant Literature Regarding Adverse Effects Associated with Vaccines — was sponsored by the Health Resources and Services Administration of the U.S. Department of Health and Human Services.

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide independent, objective analysis and advice to the nation to solve complex problems and inform public policy decisions related to science, engineering, and medicine. They operate under an 1863 congressional charter to the National Academy of Sciences, signed by President Lincoln.



[Release of 2024 U.S. Global Health Security Strategy](#)

Fact Sheet U.S. Bureau of Global Health Security and Diplomacy

April 16, 2024

Strengthening global health security is a U.S. national security priority, essential for protecting the health, lives, and economic wellbeing of Americans and people around the world. Building on the [National Biodefense Strategy](#) and [National Security Memorandum-15](#), the 2024 GHSS outlines the United States' approach to strengthening global health security capacities and to improving our collective ability to prevent, detect, and respond to new and emerging infectious disease threats around the world. Bilateral, regional, and global partnerships are central to this strategic approach.

GHSD is coordinating efforts across the State Department to contribute to the three core goals of the Strategy:

- 1. Strengthen global health security capacities through bilateral partnerships:** Through GHSD, the State Department works through diplomatic channels to strengthen prevention and preparedness to global health security threats, including HIV/AIDS. GHSD leverages and helps coordinate [U.S. government activities supporting health security strengthening](#) in collaboration with 50 countries and regional entities. The State Department is also working with other countries and stakeholders to catalyze health security progress in an additional 50 countries. Through its 55 bilateral relationships through the President's Emergency Plan for AIDS Relief (PEPFAR), the State Department is working with partners to end HIV/AIDS as a public health threat by 2030.
- 2. Catalyze political commitment, financing, and leadership to achieve health security:** Through the Bureau of Global Health Security and Diplomacy, the State Department and partners around the world launched the Foreign Ministry Channel for Global Health Security in March 2024, to focus diplomatic attention and action on critical global health security priorities. The Bureau of Global Health Security and Diplomacy leads the Department of State's efforts at the Pandemic Fund, in coordination with the U.S. Department of the Treasury. Since its launch in September 2022, the Pandemic Fund has provided \$338 million in grants to 37 countries, and an additional \$500 million will be provided this year to support national and regional priorities of low- and middle-income countries surveillance, laboratory capacity, workforce, One Health, risk communication, risk management, and community engagement for pandemic preparedness. Amb. Nkengasong represents the U.S. government on Pandemic Fund's Governing Board and co-chairs the strategic plan working group. The Department also supports the United States' efforts towards concluding a Pandemic Accord and amended International Health Regulations by the May 2024 deadline.
- 3. Increase linkages between health security and complementary programs to maximize impact:** The Bureau is focused on strengthening the linkages across global health programs, including between the U.S. PEPFAR and other global health security programs. PEPFAR reflects the U.S. government's bipartisan leadership in ending HIV/AIDS as a public health threat by 2030, increasing our impact to move pandemics from crisis toward control. Longstanding PEPFAR investments in strengthening health systems, including directly supporting 327,000 health workers in fiscal year 2023 alone, have also enabled partner countries to respond quickly and effectively to COVID-19, Ebola, H1N1 influenza, tuberculosis, and other health threats.

For more information, please see the U.S. Global Health Security Strategy [website](#). For further information, please contact ghsd_publicaffairs@state.gov.

Issued by Ambassador Dr. John Nkengasong — U.S. Global AIDS Coordinator and Senior Bureau Official for the Bureau of Global Health Security and Diplomacy (GHSD), who leads the Department's Bureau for Global Health Security and Diplomacy — took part in a White House event officially launching the 2024 U.S. Global Health Security Strategy (GHSS). Amb. Nkengasong spoke at the event alongside U.S. National Security Advisor Jake Sullivan, U.S. Coordinator for Global Health

Security Dr. Stephanie Psaki, U.S. Department of Health and Human Services Assistant Secretary for Global Affairs Loyce Pace, U.S. Agency for International Development Assistant Administrator for Global Health Dr. Atul Gawande, U.S. Centers for Disease Control and Prevention Director Dr. Mandy Cohen, and Maj. Gen. (ret) Paul Friedrichs, Director of the White House Office of Pandemic Preparedness and Response Policy.

[Secretary Becerra Statement on U.S. Global Health Security Strategy](#)

April 16, 2024 News Release

.....
.....
.....

Polio – PHEIC

[Polio this week as of 17 Apr 2024 - GPEI](#)

Headlines

No new digest content identified.

Summary of new polioviruses this week, cases and positive environmental isolates:

- DR Congo: one cVDPV1 case
- Chad: one cVDPV2 case
- Nigeria: one cVDPV2 case

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

WHO & Regional Offices [to 20 Apr 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

18 April 2024 *Departmental news*

[WHO prequalifies new oral simplified vaccine for cholera](#)

18 April 2024 *Departmental news*

[WHO launches first ever Patient Safety Rights Charter](#)

18 April 2024 *News release*

[Leading health agencies outline updated terminology for pathogens that transmit through the air](#)

18 April 2024 *Departmental news*

[Human-Animal Interface Newsletter: Jan-Mar 2024](#)

17 April 2024 *Departmental news*

[**The Quadripartite organizations announce the second Term members of its One Health High-Level Expert Panel \(OHHLEP\)**](#)

17 April 2024 *Departmental news*

[**Statement on the outcomes of the ICMRA-WHO joint workshop on COVID-19 vaccines strain change**](#)

15 April 2024 *Departmental news*

[**Special programme on sexual and reproductive health reports on year of progress**](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

No new digest content identified.

WHO Region of the Americas PAHO

:: [**Despite vaccination gains, 1.2 million children under one remain unprotected in the Americas**](#)

Washington D.C. 18 April 2024 (PAHO/WHO) – With 15 out of every 100 children in the Americas only partially protected against vaccine-preventable diseases, the Pan American Health Organization (PAHO) Director, Dr. Jarbas Barbosa, has urged countries of the region to continue efforts to recover routine vaccination coverage. "Historically, our...

:: [**PAHO shares innovative country experiences to promote vaccination in the Americas**](#)

Washington, D.C., April 16, 2024. In the context of the 22nd Vaccination Week in the Americas, celebrated from 20-27 April, the Pan American Health Organization (PAHO) is sharing more than 15 innovative experiences that countries in the Region have implemented to promote vaccination in their communities. The slogan of the week this year is...

:: [**PAHO presents key recommendations to increase equitable access to health at G20 event in Brazil**](#)

Brasilia, April 15, 2024 - The Pan American Health Organization (PAHO) recently presented a series of recommendations at G20 events in Brazil to strengthen equity in access to digital health, expand innovation and production of health technologies, tackle antimicrobial resistance, increase health investment and ensure greater retention of health...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

No new digest content identified.

WHO Eastern Mediterranean Region EMRO

No new digest content identified.

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations.

[Multi-country outbreak of cholera, External situation report #13 - 17 April 2024](#)

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

[19 April 2024 | Avian Influenza A\(H9N2\) - Viet Nam](#)

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 99, No. 16, pp. 185-192 19 April 2024

PDF: <https://iris.who.int/bitstream/handle/10665/376566/WER9916-eng-fre.pdf>

:: Summary report of the 24th and 25th meetings of the WHO Advisory Committee on Variola Virus Research

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

18 April 2024

[Community conversation kit: everyday conversations to protect community health against infectious disease](#)

18 April 2024

[Elimination of malaria and prevention of re-establishment in Sri Lanka](#)

18 April 2024

[WHO pharmaceuticals newsletter - No. 2, 2024](#)

17 April 2024

[WHO Data quality assessment of national and partner monitoring data and system implementation tool –...](#)

16 April 2024

[Technical assistance to accelerate the implementation of WHO recommendations on HIV testing and treatment...](#)

16 April 2024

[Revising the procedures for updating WHO's model lists of essential medicines: consultation report, Geneva,...](#)

16 April 2024

[Expanded programme on Immunization \(EPI\) factsheet 2023: Timor-Leste](#)

16 April 2024

[Patient safety rights charter](#)

Overview

The Patient safety rights charter is a key resource intended to support the implementation of the Global Patient Safety Action Plan 2021–2030: Towards eliminating avoidable harm in health care. The Charter aims to outline patients' rights in the context of safety and promotes the upholding of these rights, as established by international human rights standards, for everyone, everywhere, at all times.

PDF: <https://iris.who.int/bitstream/handle/10665/376539/9789240093249-eng.pdf?sequence=1>

15 April 2024

[Report of a workshop to launch the Global Oversight Committee and the Supply Chain Technical Support...](#)

.....
.....

USA – HHS, FDA, CDC

HHS

News

[Release of 2024 U.S. Global Health Security Strategy](#)

Fact Sheet Bureau of Global Health Security and Diplomacy
April 16, 2024

[Secretary Becerra Statement on U.S. Global Health Security Strategy](#)

April 16, 2024 News Release

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

[Vaccines and Related Biological Products Advisory Committee May 16, 2024 Meeting Announcement - 05/16/2024](#)

CDC/ACIP [U.S.] [to 20 Apr 2024]

<http://www.cdc.gov/media/index.html>

Latest News Releases

No new digest content identified.

ACIP Meetings

Next ACIP Meeting

June 26-28

MMWR Weekly

<https://www.cdc.gov/mmwr/index2023.html>

April 18, 2024 / No. 15

[PDF of this issue](#)

- [Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron–Associated Hospitalization in Children and Adolescents — United States, 2021–2023](#)
- [COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19–Associated Hospitalization Among Residents in Nursing Homes — National Healthcare Safety Network, United States, October 2023–February 2024](#)
- [Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023](#)

.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

[COVID-19 vaccine strain updates: Global regulators agree on timing and data requirements](#)

Report on COVID-19 vaccine strain updates: global regulators agree on timing and data requirements

17 April 2024

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

Assessment

[Global technical consultation report on proposed terminology for pathogens that transmit through the air](#)

18 Apr 2024

This global technical consultation report brings together viewpoints from experts spanning a range of disciplines with the key objective of seeking consensus regarding the terminology used to describe the transmission of pathogens through the air that can potentially cause infection in humans.

Assessment

[Efficacy, effectiveness and safety of HPV vaccination in women with conisation: a systematic review and meta-analyses](#)

17 Apr 2024

The objective of this review was to investigate the efficacy, effectiveness and safety of HPV vaccination in women undergoing conisation compared with those not receiving a HPV vaccination.

.....

Africa CDC [to 20 Apr 2024]

<https://africacdc.org/>

Press Releases, Statements [Selected]

[JOINT PRESS RELEASE | Supporting Immediate Emergency Response for Cross Border Communities in Eastern Africa](#)

19 April 2024

Statement

[Africa CDC's Statement on Moderna's plan to reassess commitment to African vaccine manufacturing](#)

15 April 2024

Africa CDC notes with disappointment that Moderna has put its plans to establish vaccine manufacturing in Kenya on hold. While we acknowledge that the need and demand for COVID-19 vaccines has indeed decreased significantly, both in Africa and globally, it is important that we reflect on the nuances of this.

The Africa CDC recalls the considerable efforts of Africa to timely access vaccines as Member States of the Union considered vaccines as the most effective means in the pandemic response. Through its Heads of States and Government, the AU and Africa CDC called for equitable and timely access to and receipt of vaccines. A call which in many instances went unanswered by the international community and industry.

It is public evidence that Covid-19 vaccines were delivered late to Africa, long after vaccines were made available to the developed world. Such actions significantly contributed to lower the demand for vaccines once these eventually were made available for Africa. We must also acknowledge that this late availability of vaccines to Africa, significantly affected the course of the pandemic, as well as the uptake and demand for vaccines.

With the view to mobilise funds and find a responsive solution, African Union established the AU Covid-19 response fund and launched the African Vaccine Acquisition Trust (AVAT) with the African Export and Import Bank (Afrexim Bank). AVAT acquired 400 million vaccines from manufacturers other than Moderna, simply because Moderna vaccines were not made available, despite attempts to buy. In fact, less than 5% of the covid-19 vaccines administered in Africa, were from Moderna. Despite these African efforts, Covid-19 vaccines were still delivered late to Africa, long after vaccines were made available to the developed world.

Through its consortium for Covid-19 Vaccine Clinical Trials (CONCVACT) Africa CDC also played a coordination role in facilitating the start and successful completion of clinical trials during the pandemic, strengthening enablers of high-quality vaccines clinical trials on the continent, and in accelerating post-trial vaccines regulatory approval.

Therefore, to blame Africa and Africa CDC for lack of demand for covid-19 vaccines and therefore the reason to put on hold plans to manufacture vaccines in Africa, only serves to perpetuate the inequity that characterized the response to the Covid-19 pandemic. While other vaccine manufacturers are progressing with their plans and construction in Africa, Moderna is abandoning a commitment to build highly needed and relevant vaccine manufacturing capabilities in Africa, in truth, demonstrating that Moderna's commitment is in fact not to vaccine equity and access to vaccines, through building manufacturing in Africa...

Articles

[Building Sustainable Vaccine Manufacturing in Africa: Africa CDC at the World Vaccine Congress, USA](#)

14 April 2024

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 20 Apr 2024]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 20 Apr 2024]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

Weekly Reports: Current Volume (6)

2024-04-19 / No. 16 WORLD IMMUNIZATION WEEK ISSUE

[View PDF of this issue](#)

- [Preplanned Studies: Impact of National Immunization Strategies on Vaccine-Preventable Diseases — China, 1950–2021](#)
- [Vital Surveillances: Thirty Years of Experience of Acute Flaccid Paralysis Surveillance for Polio — China, 1993–2022](#)
- [Methods and Applications: Comparison of Statistical Signal Detection Methods in Adverse Events Following Immunization — China, 2011–2015](#)
- [Review: A Scoping Review of Real-World Study in Vaccine Evaluation](#)

⋮
⋮

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

⋮
⋮

Organization Announcements

Paul G. Allen Frontiers Group [to 20 Apr 2024]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 20 Apr 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

Press release Apr 18, 2024

[The Bill & Melinda Gates Foundation and European Investment Bank Launch Pilot in Africa to Improve Women Entrepreneurs' Access to Capital](#)

Bill & Melinda Gates Medical Research Institute [to 20 Apr 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of

mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
News: Articles and Publications
No new digest content identified.

CARB-X [to 20 Apr 2024]

<https://carb-x.org/>

News

04.18.2024 |

[CARB-X funds Scout to develop a low-cost point-of-care diagnostic for gonorrhea](#)

CARB-X is awarding Scout up to US\$1M to demonstrate proof-of-concept and feasibility ahead of development of a new point-of-care test.

CEPI – Coalition for Epidemic Preparedness Innovations [to 20 Apr 2024]

<http://cepi.net/>

Latest News

No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to

20 Apr 2024]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 20 Apr 2024]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 20 Apr 2024]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 20 Apr 2024]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 20 Apr 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 20 Apr 2024]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 20 Apr 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

No new digest content identified.

Fondation Merieux [to 20 Apr 2024]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 20 Apr 2024]

<https://www.gavi.org/>

Press Releases

18 April 2024

[**Gavi and UNICEF welcome approval of new oral cholera vaccine**](#)

GE2P2 Global Foundation [to 20 Apr 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – March 2024](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 17 April 2024 – Issue 16](#)

Gavi [to 20 Apr 2024]

<https://www.gavi.org/>

Press Releases

18 April 2024

[**Gavi and UNICEF welcome approval of new oral cholera vaccine**](#)

GHIT Fund [to 20 Apr 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 20 Apr 2024]

<https://www.theglobalfund.org/en/news/>

News & Stories

17 April 2024

[New Nets Prevent 13 Million Malaria Cases in Sub-Saharan Africa](#)

The New Nets Project, an initiative funded by Unitaid and the Global Fund and led by the Innovative Vector Control Consortium (IVCC), piloted the use of dual-insecticide in malaria-endemic countries between 2019 and 2022 to address the growing threat...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 20 Apr 2024]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 20 Apr 2024]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 20 Apr 2024]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 20 Apr 2024]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IAVI [to 20 Apr 2024]

<https://www.iavi.org/>

News, Features

No new digest content identified.

INSERM [to 20 Apr 2024]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

17 April 2024

[ICMRA-WHO COVID-19 vaccine strain update workshop report](#)

17 April 2024

[10th ICMRA Teleconference Minutes COVID-19 Real-World Evidence observational studies Working Group](#)

ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [to 20 Apr 2024]

<https://www.ich.org/page/press-releases>
News/Pubs/Press Releases [Selective]
No new digest content identified.

ICRC [to 20 Apr 2024]

<https://www.icrc.org/en/whats-new>
What's New [Selected]

[ICRC President Mirjana Spoljaric: "War without limits equals suffering without end"](#)

ICRC Statement at the 148th Assembly of the Inter-Parliamentary Union. Special High-Level Intervention on the Geneva Conventions.
16-04-2024 | Statement

IFFIm

<http://www.iffim.org/>
Press Releases/Announcements
No new digest content identified.

IFRC [to 20 Apr 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>
Press Releases [Selected]
No new digest content identified.

Institut Pasteur [to 20 Apr 2024]

<https://www.pasteur.fr/en/press-area>
Press Documents
No new digest content identified.

ISC / International Science Council [to 20 Apr 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
Latest Updates
Blogs

[Barcelona Declaration: open research information must be the new norm](#)

The Barcelona Declaration is an initiative developed by a team of research information specialists, aimed at democratizing access to research information. This includes bibliographic metadata, funding details, and impact data, which are often inaccessible due to proprietary infrastructures.
16.04.2024

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 20 Apr 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 20 Apr 2024]

<http://www.ivi.int/>

IVI News & Announcements

EuBiologics' simplified OCV achieves WHO PQ

:: Euvichol-S, developed jointly by EuBiologics and IVI, improves productivity by approximately 40% over Euvichol-Plus®

:: Production and supply of Euvichol-S expected to help address cholera vaccine shortages

April 15, 2024, SEOUL, Republic of Korea – EuBiologics and the International Vaccine Institute (IVI) announced that Euvichol-S, an improved oral cholera vaccine (OCV) developed jointly by EuBiologics and IVI, has achieved World Health Organization prequalification (PQ). Euvichol-S is a new OCV that has improved productivity by about 40 percent over the existing Euvichol-Plus® by modifying the formulation and manufacturing method of the original vaccine material...

Johns Hopkins Center for Health Security [to 20 Apr 2024]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 20 Apr 2024]

<http://www.msf.org/>

Latest [Selected Announcements]

Myanmar

MSF office and pharmacy in Rakhine state destroyed in fire amid ongoing violence

Press Release 16 Apr 2024

Myanmar

Five things to know about the humanitarian crisis in northern Rakhine

Interview 15 Apr 2024

National Academy of Medicine - USA [to 20 Apr 2024]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 20 Apr 2024]

<https://www.nationalacademies.org/newsroom?>

News

[New Comprehensive Review Examines Potential Harms of COVID-19 Vaccination and Intramuscular Vaccination](#)

News Release | April 16, 2024

National Vaccine Program Office - U.S. HHS [to 20 Apr 2024]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

June 13-14, 2024

NIH [to 20 Apr 2024]

<http://www.nih.gov/>

New Releases

No new digest content identified.

Sabin Vaccine Institute [to 20 Apr 2024]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 20 Apr 2024]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

17 April 2024

[Navigating HIV services during migration crisis in Eastern Europe and Central Asia](#)

16 April 2024 *Press statement*

[UNAIDS calls for sustained and expanded health and HIV investments at the Spring Meetings of the IMF and World Bank](#)

Debt restructuring and reforms to the global tax system are urgently required to finance health systems and other essential services

UNICEF [to 20 Apr 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Press release 19 April 2024

[Finance Ministers from Latin America and the Caribbean Target US\\$372 Billion Investment in Water and Sanitation](#)

WASHINGTON, D.C., 19 April 2024 – Finance ministers from across Latin America and the Caribbean convened today in Washington, D.C., to discuss mobilizing US\$372 billion over the next five years to combat the region's water and sanitation crisis. The meeting, which gathered close to 100 ministers and development partners, was hosted by the Inter-...

Statement 17 April 2024

[Gavi and UNICEF welcome approval of new oral cholera vaccine](#)

GENEVA/NEW YORK, 18 April 2024 – Gavi, the Vaccine Alliance and UNICEF welcome the news that a new oral cholera vaccine (OCV), Euvichol-S, has now received WHO prequalification and can be made available to countries around the world. The prequalification of this new product will help EuBiologics, the manufacturer, produce more volumes of vaccine,...

Remarks 15 April 2024

[UNICEF Deputy Executive Director Ted Chaiban remarks at the International Conference for Sudan and the Neighbouring Countries](#)

PARIS, 15 April 2024 - "Excellencies, 14 million Sudanese children in urgent need of humanitarian aid. 4.6 million children displaced by conflict with 1.1 million seeking refuge in neighbouring countries, the largest child displacement crisis globally. "Almost 4 million children suffering from acute malnutrition, with 730,000 facing life-...

Unitaid [to 20 Apr 2024]

<https://unitaid.org/>

Featured News

18 April 2024

[Unitaid and ANRS MIE Forge Stronger Collaboration to Combat Infectious Diseases](#)

17 April 2024

[New Nets Prevent 13 Million Malaria Cases in Sub-Saharan Africa](#)

Compared to standard nets, the introduction of 56 million state-of-the-art mosquito nets in 17 countries across sub-Saharan Africa averted an estimated 13 million malaria cases and 24,600 deaths.

16 April 2024

[Unitaid and Expertise France announce the launch of Phase II of the SUCCESS program for the elimination of cervical cancer in ten low-resource countries](#)

...This innovative project adopts an integrated approach, deploying effective screening and treatment tools, integrating these services into existing healthcare systems, and strengthening awareness and community engagement to increase demand for cervical cancer prevention. By leveraging the lessons from the first phase, SUCCESS 2 aims to extend its impact to contribute significantly to the elimination of cervical cancer on a larger scale...

Vaccine Equity Cooperative [nee Initiative] [to 20 Apr 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 20 Apr 2024]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 20 Apr 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 20 Apr 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 20 Apr 2024]

<https://wellcome.org/>

News, Opinion, Reports

No new digest content identified.

The Wistar Institute [to 20 Apr 2024]

<https://www.wistar.org/news/press-releases>

No new digest content identified.

World Bank [to 20 Apr 2024]

<http://www.worldbank.org/en/news/all>

All News [Selected]

[World Bank Group Aims to Expand Health Services to 1.5 Billion People](#)

Date: April 18, 2024 Type: Factsheet

The World Bank Group announced an ambitious plan to support countries in delivering quality, affordable health services to 1.5 billion people by 2030. This is part of a larger global effort to provide a basic standard of care through every stage of a person’s life – infancy, childhood, adolescence, and adulthood.

For decades, the World Bank Group has helped provide health services for women and children in more than 100 countries. A focused effort to become faster, work better with partners, and bring in the private sector has enabled the 80-year-old institution to pursue greater scale and impact.

The strategy to reach 1.5 billion people is focused on three core elements:

:: Expanding focus from maternal and child health to include coverage throughout a person’s lifetime, including non-communicable diseases.

:: Expanding operations to hard-to-reach areas, including remote villages, cities, and countries.

:: Working with governments to cut unnecessary fees and other financial barriers to health care.

To be counted toward this goal, a person must be seen and treated by a health-care worker via an in-person visit or telehealth...

WFPHA: World Federation of Public Health Associations [to 20 Apr 2024]

<https://www.wfpha.org/>

Event

[Webinar: Secure Futures: Bridging Sustainable Investment in Immunization and Defense Strategies](#)

Apr 17, 2024

Date and Time: 7th May 2024 | 17:00-18:00 (EST) Event Description: In this enlightening webinar, we delve into the strategic parallels between...

[World Medical Association \[WMA\]](#) [to 20 Apr 2024]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health [to 20 Apr 2024]

<https://www.oie.int/en/>

Press Releases, Statements

No new digest content identified.

.....
.....

ARM [Alliance for Regenerative Medicine] [to 20 Apr 2024]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 20 Apr 2024]

<https://www.bio.org/press-releases>

Press Releases

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 20 Apr 2024]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 20 Apr 2024]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 20 Apr 2024]

<https://ifpma.org/>

News

No new digest announcements identified.

International Alliance of Patients' Organizations – IAPO [to 20 Apr 2024]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 20 Apr 2024]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases

[AstraZeneca advances the science of infectious disease protection at ECCMID 2024](#)

17 April 2024

:: Real-world effectiveness data on Beyfortus reinforce the impact of passive immunisation protecting infants from RSV hospitalisation

:P: Updated real-world data demonstrate continued risk of severe COVID-19 outcomes among immunocompromised populations

Bharat Biotech

Press Releases - *No new digest announcements identified.*

BioCubaFarma – Cuba

Últimas Noticias - *No new digest announcements identified*

Biological E

News - *No new digest announcements identified.*

BioNTech

Press Releases - *No new digest announcements identified.*

Boehringer

Press Releases - *No new digest announcements identified.*

CanSinoBIO

News - *Website not responding at inquiry*

CIGB

Latest News - *No new digest announcements identified.*

Cinnagen

Recent News - *No new digest announcements identified.*

Clover Biopharmaceuticals – China

News - *No new digest announcements identified.*

Curevac [Bayer Ag – Germany]

News

April 16, 2024

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

:: Agreement creates strong synergies between CureVac's unique end-to-end mRNA capabilities and MD Anderson's translational and clinical research expertise
:: Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need
:: MD Anderson responsible for leading initial Phase 1/2 studies; CureVac retains worldwide exclusive rights to late-stage development, commercialization, or partnering of cancer vaccine candidates

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified
<https://sputnikvaccine.com/> - No new digest announcements identified

GSK

Press releases for media

17 April 2024

New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade

End-of-trial data show 79.7% efficacy in participants aged 50 years and over, six to 11 years after vaccination.

16 April 2024

GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA

Prescription Drug User Fee Act action date set by FDA for 14 February 2025.

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified.

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases

Apr 18, 2024

Statement COVID-19

[Novavax to Supply Updated COVID-19 Vaccine to Private Healthcare Providers in the United Kingdom](#)

Pfizer

Recent Press Releases - No new digest announcements identified

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS

April 16, 2024

[Serum Institute of India and University of Oxford Strike Landmark Licensing Agreement for Meningitis-B Vaccine](#)

Serum Institute of India Pvt. Ltd (SIIPL), in collaboration with the University of Oxford, is developing a novel solution for Men-B disease, advancing global accessibility to life-saving vaccines.

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

SK Biosciences

Press Releases - No new digest announcements identified.

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases - No new digest announcements identified.

Vector State Research Centre of Virology and Biotechnology

Home - Website not responding [404 error]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....

.....

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

[:: Organization Announcements](#)

[:: Journal Watch](#)

[:: Pre-Print Servers](#)



Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 4: E275-359 April 2024

<https://journalofethics.ama-assn.org/issue/critical-pedagogies-health-professions-education>

Global Medical Supply Chain Security

Individual patients' safety and public health were compromised by critical drug shortages, substandard medications, and extremely restricted access to personal protective equipment during the COVID-19 pandemic. As health organizations and workers struggled to meet demands posed by unprecedented patient numbers and illness acuity, our complex global health ecosystem with long-standing upstream supply chain vulnerabilities failed to meet emergent downstream demand in several ways. First, material procurement and ingredient sourcing were inadequate. Second, operations lacking transparency made stopping propagation of substandard or falsified medications ineffective, inefficient, or impossible. Finally, logistical obfuscation made environmental consequences of waste management hard to assess and steward responsibly. Policy makers, health care organizations, regulators, manufacturers, and distributors each have roles in building and maintaining global medical supply chain security. This theme issue investigates how these and other agents' failures to cultivate public health capacity, nourish sustainable production processes, and carefully maintain systemic supply chain resiliency are neither accidental nor simply unfortunate, but unjust.

American Journal of Human Genetics

Apr 04, 2024 Volume 111 Issue 4 p621-806

<https://www.cell.com/ajhg/current>

[Reviewed earlier]

American Journal of Infection Control

April 2024 Volume 52 Issue 4p 381-499

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

April 2024 Volume 66 Issue 4p 573-750

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

May 2024 114(5)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 110 (2024): Issue 4 (Apr 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/4/tpmd.110.issue-4.xml>

[Reviewed earlier]

Annals of Internal Medicine

April 2024 Volume 177, Issue 4

<https://www.acpjournals.org/toc/aim/current>

Original Research

[Clinical Outcomes With Electronic Nudges to Increase Influenza Vaccination - A Prespecified Analysis of a Nationwide, Pragmatic, Registry-Based, Randomized Implementation Trial](#)

Niklas Dyrby Johansen, MD, Muthiah Vaduganathan, MD, MPH, Ankeet S. Bhatt, MD, MBA, ScM, ...
et al.

Pages:476–483

Conclusion:

In a prespecified exploratory analysis, modest increases in influenza vaccination rates seen with electronic nudges did not translate into observable improvements in clinical outcomes. Seasonal influenza vaccination should remain strongly recommended.

Special Articles

[Putting Adult Vaccine Recommendations Into Action](#)

Christine Laine, MD, MPH, Amir Qaseem, MD, PhD, MHA, Darilyn V. Moyer, MD

Pages:527–528 13 February 2024

Artificial Intelligence – An International Journal

Volume 330 May 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/330/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 20 Apr 2024)
[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 20 Apr 2024)

[Health workforce strategies during COVID-19 response: insights from 15 countries in the WHO Africa Region](#)

The COVID-19 pandemic unveiled huge challenges in health workforce governance in the context of public health emergencies in Africa. Several countries applied several measures to ensure access to qualified and...

Authors: Adam Ahmat, Sunny C Okoroafor, James Avoka Asamani, Millogo Jean, Abdou Illou Mourtala, Jennifer Nyoni and Kasonde Mwinga

Citation: BMC Health Services Research 2024 24:470

Content type: Research Published on: 15 April 2024

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 20 Apr 2024)

[Modelling the impact of hybrid immunity on future COVID-19 epidemic waves](#)

Since the emergence of SARS-CoV-2 (COVID-19), there have been multiple waves of infection and multiple rounds of vaccination rollouts. Both prior infection and vaccination can prevent future infection and redu...

Authors: Thao P. Le, Isobel Abell, Eamon Conway, Patricia T. Campbell, Alexandra B. Hogan, Michael J. Lydeamore, Jodie McVernon, Ivo Mueller, Camelia R. Walker and Christopher M. Baker

Citation: BMC Infectious Diseases 2024 24:407

Content type: Research Published on: 16 April 2024

[The global patent landscape of emerging infectious disease monkeypox](#)

Monkeypox is an emerging infectious disease with confirmed cases and deaths in several parts of the world. In light of this crisis, this study aims to analyze the global knowledge pattern of monkeypox-related patents and explore current trends and future technical directions in the medical development of monkeypox to inform research and policy.

Authors: Yuanqi Cai, Xiaoming Zhang, Kuixing Zhang, Jingbo Liang, Pingping Wang, Jinyu Cong, Xin Xu, Mengyao li, Kunmeng Liu and Benzhen Wei

Citation: BMC Infectious Diseases 2024 24:403

Content type: Research Published on: 15 April 2024

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmmedethics/content>

(Accessed 20 Apr 2024)

[Research ethics and artificial intelligence for global health: perspectives from the global forum on bioethics in research](#)

The ethical governance of Artificial Intelligence (AI) in health care and public health continues to be an urgent issue for attention in policy, research, and practice. In this paper we report on central theme...

Authors: James Shaw, Joseph Ali, Caesar A. Atuire, Phaik Yeong Cheah, Armando Guio Español, Judy Wawira Gichoya, Adrienne Hunt, Daudi Jjingo, Katherine Littler, Daniela Paolotti and Effy Vayena

Citation: BMC Medical Ethics 2024 25:46
Content type: Research Published on: 18 April 2024

BMC Medicine

<http://www.biomedcentral.com/bmcmmed/content>

(Accessed 20 Apr 2024)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 20 Apr 2024)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 20 Apr 2024)

[Knowledge and trust of mothers regarding childhood vaccination in Rwanda](#)

Knowledge and trust are some of the contributing factors to vaccine acceptance(VA) and Vaccine hesitancy (VH) is one of the top threats to global health. A significant drop in childhood vaccination has been ob...

Authors: Edward Mbonigaba, Fengyun Yu, Mark Donald C Reñosa, Frederick Nchang Cho, Qiushi Chen, Claudia M Denking, Shannon A McMahan and Simiao Chen

Citation: BMC Public Health 2024 24:1067

Content type: Research Published on: 17 April 2024

[The 5 C model and Mpox vaccination behavior in Germany: a cross-sectional survey](#)

Due to the authorization of the Mpox vaccines, we aimed to identify determinants of the intention to get vaccinated, actively trying to receive vaccination, and for successfully receiving a vaccination in Germ...

Authors: Philip Oeser, Julianna Grune, Jendrik Dedow and Wolfram Joachim Herrmann

Citation: BMC Public Health 2024 24:1039

Content type: Research Published on: 15 April 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcrenotes/content>

(Accessed 20 Apr 2024)

[No new digest content identified]

BMJ Evidence-Based Medicine

April 2024 - Volume 29 - 2

<https://ebm.bmj.com/content/29/2>

[Reviewed earlier]

BMJ Global Health

April 2024 - Volume 9 - Suppl 1

https://gh.bmj.com/content/9/Suppl_1

Social determinants of health equity

Analysis

[The cost of inaction on health equity and its social determinants](#) (8 April, 2024)

Pooja Yerramilli, Mickey Chopra, Kumanan Rasanathan

Bulletin of the Atomic Scientists

March 2024

<https://thebulletin.org/magazine/2024-03/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(4); 2024 Apr 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/458786/>

[Reviewed earlier]

Cell

Mar 28, 2024 Volume 187 Issue 7 p1567-1818

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 50, Issue 3 May 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 115, Issue 5 Pages: 907-1175 May 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Mini Review

[Summary Report of a Public Workshop: Case Studies of Multi-Regional Clinical Trial Incorporating Concept of the ICH E17 Guideline](#)

Nobuko Matsushima, Yasuto Otsubo, Yoko Aoi, Ryuta Nakamura, Shuhei Kaneko, Takashi Asakawa, Nobushige Matsuoka, Kei Watabe, Osamu Komiyama, Hideharu Yamamoto, Yuki Ando
Pages: 965-970

First Published: 22 January 2024

Abstract

To further our understanding of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) E17 guideline and promote effective implementation, a public workshop was held in Japan by regulatory agency and industry representatives. In this workshop, important concepts explained in the ICH E17 guideline, such as intrinsic/extrinsic ethnic factors that influence treatment effects ("effect modifiers") and the holistic evaluation of consistency of treatment effect were actively discussed through case studies. The importance of holistic evaluation of consistency was recognized, and it was concluded that the evaluation and relevant discussion should be shared with regulatory authorities, sponsors, and broader stakeholders.

Clinical Therapeutics

March 2024 Volume 46 Issue 3 p185-304
<http://www.clinicaltherapeutics.com/current>
[Reviewed earlier]

Clinical Trials

Volume 21 Issue 2, April 2024
<https://journals.sagepub.com/toc/ctja/21/2>
[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>
[Accessed 20 Apr 2024]

[How integration of refugees into national health systems became a global priority: a qualitative policy analysis](#)

Despite a long history of political discourse around refugee integration, it wasn't until 2016 that this issue emerged as a global political priority. Limited research has examined the evolution of policies of...

Authors: Shatha Elnakib, Caitlin Jackson, Ummekulsoom Lalani, Yusra Ribhi Shawar and Sara Bennett

Citation: Conflict and Health 2024 18(Suppl 1):31

Content type: Research Published on: 15 April 2024

[The emergence and regression of political priority for refugee integration into the Jordanian health system: an analysis using the Kingdon's multiple streams model](#)

The prolonged presence of Syrian refugees in Jordan has highlighted the need for sustainable health service delivery models for refugees. In 2012, the Jordanian government adopted a policy that granted Syrian ...

Authors: Shatha Elnakib, Laila Akhu-Zaheya, Wejdan Khater, Lama Bou-Karroum, Gladys Honein-AbouHaidar, Sabine Salameh, Yusra Ribhi Shawar and Paul Spiegel

Citation: Conflict and Health 2024 18(Suppl 1):30

Content type: Research Published on: 15 April 2024

Contemporary Clinical Trials

Volume 138 March 2024
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/1387/suppl/C>
[Reviewed earlier]

The CRISPR Journal

Volume 7, Issue 2 / April 2024
<https://www.liebertpub.com/toc/crispr/7/2>
[New issue; No digest content identified]

Current Genetic Medicine Reports

Volume 11, issue 1-2, June 2023
<https://link.springer.com/journal/40142/volumes-and-issues/11-1>
[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 3 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

April 2024 - Volume 37 - Issue 2

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 20 Apr 2024]

[No new digest content identified]

Developing World Bioethics

Volume 24, Issue 1 Pages: 1-48 March 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

Access to Essential Medicines for Global Health and the Human Right to Health

[Reviewed earlier]

Development in Practice

Volume 34, Issue 2, 2024

<https://www.tandfonline.com/toc/cdip20/34/2>

[Reviewed earlier]

Development Policy Review

Volume 42, Issue 2 March 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 48, Issue 2 April 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/2>

[Reviewed earlier]

EMBO Reports

Volume 25 Issue 4 20 April 2024

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 30, Number 4—April 2024

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 46 March 2024

<https://www.sciencedirect.com/journal/epidemics/vol/46/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 2 Pages: 1-35 March–April 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

Indigenous data sovereignty :: Returning clinically relevant results

[Reviewed earlier]

Ethics & International Affairs

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 2, April 2024

[Reviewed earlier]

Expert Review of Vaccines

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

March/April 2024 Volume 103, Number 2

<https://www.foreignaffairs.com/issues/2023/103/2>

[Reviewed earlier]

Forum for Development Studies

Volume 51, 2024 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 4 April 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/4>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 20 Apr 2024]

[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 1 February 28, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 20 Apr 2024]

[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 20 Apr 2024]

[No new digest content identified]

Health and Human Rights

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

Special Section: Economic Inequality and the Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 1 - January 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 3, April 2024

<https://academic.oup.com/heapol/issue/39/3>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 20 Apr 2024]

[No new digest content identified]

Human Gene Therapy

Volume 35, Issue 5-6 / March 2024

<https://www.liebertpub.com/toc/hum/35/5-6>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=toCList>

[Reviewed earlier]

Immunity

Mar 12, 2024 Volume 57 Issue 3 p401-612

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 20 Apr 2024]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 20 Apr 2024]

[No new digest content identified]

International Health

Volume 16, Issue 2, March 2024

<https://academic.oup.com/inthealth/issue/16/2>

[Reviewed earlier]

International Human Rights Law Review

Volume 12 (2023): Issue 2 (Dec 2023)

<https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-2.xml>

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 3 (2024): March 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/110>

[Reviewed earlier]

International Journal of Epidemiology

Volume 53, Issue 2, April 2024

<https://academic.oup.com/ije/issue/53/2>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 1 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/1>

Table of contents

[Reviewed earlier]

JAMA

April 16, 2024, Vol 331, No. 15, Pages 1257-1340

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

JAMA Health Forum

April 2024, Vol 5, No. 4

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

April 2024, Vol 178, No. 4, Pages 326-422

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBI Evidence Synthesis

March 2024 - Volume 22 - Issue 3

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

April 2024 Volume 74 Issue 4 p629-860

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 79 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 2 April 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-2>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[New issue; No digest content identified]

Journal of Development Economics

Volume 168 May 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/168/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 1-2, February–April 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

March 2024 - Volume 78 - 3

<https://jech.bmj.com/content/78/3>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 17, Issue 1 Pages: 1-235 March 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[New issue; No digest content identified]

Journal of Global Ethics

Volume 19, Issue 3 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 1, February 2024

<https://muse.jhu.edu/issue/52063>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 26, Issue 2 April 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-2>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 229, Issue 3, 15 March 2024

<https://academic.oup.com/jid/issue/229/3>

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 3 Pages: 3-1943 April 2024
<https://onlinelibrary.wiley.com/toc/10991328/current>
[Reviewed earlier]

Journal of Medical Ethics

April 2024 - Volume 50 - 4
<http://jme.bmj.com/content/current>
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 1 (2024)
<https://institutionalrepository.aah.org/jpcrr/>
[Reviewed earlier]

The Journal of Pediatrics

Volume 267 April 2024
<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/267/suppl/C>
[New issue; No digest content identified]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024) Issue 1
<https://www.tandfonline.com/toc/jppp20/17/1>
[Reviewed earlier]

Journal of Public Health Management & Practice

March/April 2024 - Volume 30 - Issue 2
<https://onlinelibrary.wiley.com/toc/10991328/current>
[Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 1, March 2024
<https://link.springer.com/journal/41271/volumes-and-issues/45-1>
[Reviewed earlier]

Journal of the Royal Society – Interface

April 2024 Volume 21 Issue 213
<https://royalsocietypublishing.org/toc/rsif/current>
[Reviewed earlier]

Journal of Travel Medicine

Volume 31, Issue 3 April 2024
<https://academic.oup.com/jtm/issue>
[Reviewed earlier]

Journal of Virology

Volume 98 • Number 2 • February 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Apr 20, 2024 Volume 403 Number 10436 p1513-1602

<https://www.thelancet.com/journals/lancet/issue/current>

Comment

[Bivalent conjugate vaccines for typhoid and paratyphoid fever](#)

Rubhana Raqib

Articles

[The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial](#)

Prasad S Kulkarni, et al, TCV-01 Study Group

Enteric fever caused by Salmonella enterica Typhi and Salmonella Paratyphi A is an important public health problem, especially in low-income and middle-income countries with limited access to safe water and sanitation. We present results from, to our knowledge, the first ever human study of a bivalent paratyphoid A-typhoid conjugate vaccine (Sii-PTCV)...

Sii-PTCV was safe and immunogenic for both typhoid and paratyphoid antigens indicating its potential for providing comprehensive protection against enteric fever.

The Lancet Child & Adolescent Health

May 2024 Volume 8 Number 5 p311-384

<https://www.thelancet.com/journals/lanchi/issue/current>

Viewpoint

[The importance of global bioethics to paediatric health care](#)

Karel-Bart Celie, Joseph W Mocharnuk, Ulrick S Kanmounye, Ruben Ayala, Tahmina Banu, Kokila Lakhoo

Summary

The paradigm of values adopted by the global health community has a palpable, albeit often unseen, impact on patient health care. In this Viewpoint, we investigate an inherent tension in the core values of medical ethics and clinical practice that could explain why paediatric health care faces resource constraints despite compelling economic and societal imperatives to prioritise child health and wellbeing. The dominant narrative in the philosophy of medicine tends to disproportionately underscore values of independence and self-determination, which becomes problematic in the context of paediatric patients, who by their very nature epitomise vulnerability and dependence. A double-jeopardy situation arises when disadvantaged children see their inherent dependence leveraged against them. We illustrate this predicament through specific examples relating to rights and obligations and to autonomy. Alternative value perspectives—communitarianism and relational autonomy—might offer more robust protection for vulnerable children. A shift away from the dominant narrative towards a more explicit and inclusive discussion of values is necessary. Such a shift requires giving a legitimate platform to diverse perspectives, with the presumption that collective moral progress is possible; this endeavour is embodied by global bioethics. Successful implementation of global bioethics, in turn, hinges on close collaboration between practicing clinicians and bioethicists. Taking global bioethics seriously and actively pursuing collaboration could help the global health community achieve more equitable health care.

Lancet Digital Health

Apr 2024 Volume 6 Number 4 e230-e298

<https://www.thelancet.com/journals/landig/issue/current>

[New issue; No digest content identified]

Lancet Global Health

May 2024 Volume 12 Number 5 e712-e890

<https://www.thelancet.com/journals/langlo/issue/current>

Comment

[A Global Tuberculosis Dictionary: unified terms and definitions for the field of tuberculosis](#)

Alberto L Garcia-Basteiro, et al.

Correspondence

[Introduction and rollout of malaria vaccines in Cameroon and Burkina Faso: early lessons learned](#)

Adidja Amani, Franck Mboussou, Benido Impouma, Joseph Cabore, Matshidiso R Moeti

Articles

[Safety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial](#)

Katerina Rok Song, et al.

Background

In October, 2017, WHO launched a strategy to eliminate cholera by 2030. A primary challenge in meeting this goal is the limited global supply capacity of oral cholera vaccine and the worsening of cholera outbreaks since 2021. To help address the current shortage of oral cholera vaccine, a WHO prequalified oral cholera vaccine, Euvichol-Plus was reformulated by reducing the number of components and inactivation methods. We aimed to evaluate the immunogenicity and safety of Euvichol-S (EuBiologics, Seoul, South Korea) compared with an active control vaccine, Shanchol (Sanofi Healthcare India, Telangana, India) in participants of various ages in Nepal.

Interpretation

A two-dose regimen of Euvichol-S vaccine was non-inferior to the active control vaccine, Shanchol, in terms of seroconversion rates 2 weeks after the second dose. The simplified formulation and production requirements of the Euvichol-S vaccine have the potential to increase the supply of oral cholera vaccine and reduce the gap between the current oral cholera vaccine supply and demand.

Funding

The Bill & Melinda Gates Foundation.

Viewpoint

[Cooperation for malaria control and elimination in the Guiana Shield](#)

Alice Sanna, et al.

Lancet Infectious Diseases

Apr 2024 Volume 24 Number 4 p329-436, e207-e267

<https://www.thelancet.com/journals/laninf/issue/current>

Comment

[The oral poliovirus vaccine—a solution and a concern for eradication](#)

Martin Faye, Maria Dolores Fernandez-Garcia

[Novel oral poliovirus vaccine type 2 is an important eradication tool, but reaching every last child remains vital](#)

Larry Kotei, Ed Clarke

Correspondence

[The role of NITAGs in government decisions on vaccine use: insights from the Fifth Global NITAG Network meeting](#)

Louise Henaff, Dace Zavadska, Mario Melgar, Johanna Fihman, Christoph Steffen, Joachim Hombach

Articles

[Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study](#)

Adedapo O Bashorun, et al.

[Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study](#)

Laura V Cooper, et al.

Personal View

[Vaccinating people living with HIV: a fast track to preventive and therapeutic HIV vaccines](#)

Alexandra Trkola, Penny L Moore

Lancet Public Health

Apr 2024 Volume 9 Number 4 e207-e274

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]

Lancet Respiratory Medicine

Apr 2024 Volume 12 Number 4 p255-336, e13-e30

<https://www.thelancet.com/journals/lanres/issue/current>

Editorial

[Ending tuberculosis: ways forward](#)

The Lancet Respiratory Medicine

[Excerpt]

...We look forward to hearing progress made by the new WHO TB vaccine accelerator council, established to ease licensing of novel vaccines (five candidates have reached phase 3 trials). M72/AS01E—the most promising candidate—is being assessed in a large RCT across Africa and Southeast Asia with the aim of preventing progression from infection to active tuberculosis in adults. Results are expected in late 2029, but phase 2b data for latent tuberculosis infection are promising (vaccine efficacy 50% [90% CI 12–71]). The WHO 5-year Flagship Initiative should help to accelerate this progress, as a call was made to license a new vaccine by 2027. In the UN high-level meeting later this year, governments will review progress and update guidance, building on commitments made in 2023, including the goal to reach 90% of people at risk with tuberculosis preventive treatment (TPT) by 2027. The new ICE-TB classification will help to identify those most likely to benefit from TPT. However, further research is needed to develop shorter, safer treatment regimens to improve completion rates.

Worldwide efforts have prevented 75 million deaths since 2000, but more funding is needed. From investing in the Global Fund, the UK managed to reduce the price and improve access to tuberculosis drugs, with a recent pledge of £1 billion for 2023–2025 to treat 1 million and screen 20 million people. Despite reversing the impact of COVID-19 on tuberculosis, most regions are far from reaching End TB Strategy targets, with LMICs receiving US\$1 billion less funding for tuberculosis services in 2022 than in 2018. At the recent UN meeting, governments promised to spend \$22 billion on tuberculosis by 2027, but \$13 billion was promised in 2018 and by 2022, less than half was mobilised.

Innovations in diagnosing tuberculosis have reached high-burden countries. The GeneXpert system provides results in 1 h, but the problem of affordability remains. Doctors Without Borders lobbied for cheaper tests—hoping to exert the same pressure that allowed generic competition for bedaquiline—and inventors of GeneXpert agreed to collaborate with the Global Fund, Stop TB Partnership, and USAID to make zero profit on standard tuberculosis cartridges, allowing 5 million tests to be acquired at a lower price.

Trials show promise for a new tuberculosis vaccine, but researchers need to consider access and affordability in LMICs. Learning from accelerated COVID-19 vaccine rollout and a comprehensive health-care approach are key. The WHO TB vaccine accelerator council must improve cooperation between funders and governments to overcome barriers to development. Tracking progress across the spectrum of disease and establishing long-term outcomes (post-tuberculosis sequelae) should be the priority. We advocate for governments to maintain accountability and focus on moving, step by step, towards eradication.

Maternal and Child Health Journal

Volume 28, Issue 3 March 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-3>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 44 Issue 3, April 2024

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 102, Issue 1 Pages: 1-269 March 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Apr 03, 2024 Volume 32 Issue 4 p857-1178

<https://www.cell.com/molecular-therapy/current>

Editorials

[FDA approval of the first cellular therapy for a solid \(non-hematologic\) cancer](#)

James N. Kochenderfer

The first US Food and Drug Administration-approved cellular therapy for treating a solid (non-hematologic) malignancy was granted accelerated approval on February 16, 2024.¹ The therapy, lifileucel (Amtagvi), is manufactured by Iovance Biotherapeutics.¹ Approval was for adult patients with unresectable or metastatic melanoma that was previously treated with standard therapies, and

approval was based on results showing an overall response rate of 31.5% (95% confidence interval: 21.1%, 43.4%).¹ The median duration of responses was not reached.

[Large-scale falsification of research papers risks public trust in biomedical sciences](#)

Rory Bricker-Anthony, Roland W. Herzog

Over the past 3 years, the editors of the *Molecular Therapy* and other leading journals have published multiple editorials about the massive volume of submissions of fake papers by the ever-growing paper mill business.^{1,2,3,4,5} In some academic systems, unrealistic expectations of scientific publishing for the purpose of graduation, career progression/promotion, and grant applications may help fuel this phenomenon. While paper mills have mostly emerged in other parts of the world, recent scandals involving individual laboratories that apparently generated entire series of papers with invented or falsified experimental data have now shaken the biomedical research community in the United States.

Commentaries

[In a quest for bivalent mRNA vaccine for respiratory viruses: An effective strategy to overcome antigenic competition](#)

Gokulnath Mahalingam, Srujan Marepally

In a world grappling with the evolving variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), another emerging respiratory virus, respiratory syncytial virus (RSV), continues to cause significant illness in millions of vulnerable people, including infants, elderly individuals, and immunocompromised people globally.¹ The situation is further complicated by the occurrence of co-infections with these viruses, which significantly worsens clinical outcomes and increases mortality rates in children.

Nature

Volume 628 Issue 8008, 18 April 2024

<https://www.nature.com/nature/volumes/627/issues/8008>

Editorial 16 Apr 2024

[How India can become a science powerhouse](#)

As the world's largest election kicks off this week, India has an opportunity to reimagine science funding.

Nature Biotechnology

Volume 42 Issue 4, April 2024

<https://www.nature.com/nbt/volumes/42/issues/4>

Correspondence Published: 19 March 2024

[Making genome editing a success story in Africa](#)

Hussein M. Abkallo,

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 20 Apr 2024)

[No new digest content identified]

Nature Genetics

Volume 56 Issue 4, April 2024

<https://www.nature.com/ng/volumes/56/issues/4>

Comment 13 Mar 2024

[Guidance on use of race, ethnicity, and geographic origin as proxies for genetic ancestry groups in biomedical publications](#)

W. Gregory Feero, Robert D. Steiner, Kirsten Bibbins-Domingo

Nature Human Behaviour

Volume 8 Issue 3, March 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/3>

[Reviewed earlier]

Nature Medicine

Volume 30 Issue 4, April 2024

<https://www.nature.com/nm/volumes/30/issues/4>

Perspective 19 Apr 2024

[Causal machine learning for predicting treatment outcomes](#)

Stefan Feuerriegel, Dennis Frauen, Mihaela van der Schaar

Abstract

Causal machine learning (ML) offers flexible, data-driven methods for predicting treatment outcomes including efficacy and toxicity, thereby supporting the assessment and safety of drugs. A key benefit of causal ML is that it allows for estimating individualized treatment effects, so that clinical decision-making can be personalized to individual patient profiles. Causal ML can be used in combination with both clinical trial data and real-world data, such as clinical registries and electronic health records, but caution is needed to avoid biased or incorrect predictions. In this Perspective, we discuss the benefits of causal ML (relative to traditional statistical or ML approaches) and outline the key components and steps. Finally, we provide recommendations for the reliable use of causal ML and effective translation into the clinic.

Articles

[Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial](#)

Treatment of patients with advanced hepatocellular carcinoma with a personalized DNA vaccine in combination with anti-PD-1 therapy was safe and led to encouraging clinical efficacy, with immunological analyses confirming the induction of tumor antigen-specific T cell responses.

Mark Yarchoan, Edward J. Gane, Niranjana Y. Sardesai

[Enhanced cholera surveillance to improve vaccination campaign efficiency](#)

A modeling study of 35 cholera-affected countries in Africa showed that introducing cholera surveillance could improve the effectiveness and cost-effectiveness of preventive cholera vaccination campaigns.

Hanmeng Xu, Kaiyue Zou, Elizabeth C. Lee

Abstract

Systematic testing for *Vibrio cholerae* O1 is rare, which means that the world's limited supply of oral cholera vaccines (OCVs) may not be delivered to areas with the highest true cholera burden. Here we used a phenomenological model with subnational geographic targeting and fine-scale vaccine effects to model how expanding *V. cholerae* testing affected impact and cost-effectiveness for preventive vaccination campaigns across different bacteriological confirmation and vaccine targeting assumptions in 35 African countries. Systematic testing followed by OCV targeting based on confirmed cholera yielded higher efficiency and cost-effectiveness and slightly fewer averted cases than status quo scenarios targeting suspected cholera. Targeting vaccine to populations with an annual incidence rate greater than 10 per 10,000, the testing scenario averted 10.8 (95% prediction

interval (PI) 9.4–12.6) cases per 1,000 fully vaccinated persons while the status quo scenario averted 6.9 (95% PI 6.0–7.8) cases per 1,000 fully vaccinated persons. In the testing scenario, testing costs increased by US\$31 (95% PI 25–39) while vaccination costs reduced by US\$248 (95% PI 176–326) per averted case compared to the status quo. Introduction of systematic testing into cholera surveillance could improve efficiency and reach of global OCV supply for preventive vaccination.

Nature Reviews Drug Discovery

Volume 23 Issue 4, April 2024

<https://www.nature.com/nrd/volumes/23/issues/4>

Review Article 23 Jan 2024

Strategies to reduce the risks of mRNA drug and vaccine toxicity

The field of nucleic acid therapeutics is rapidly expanding, with mRNA drug and vaccine candidates now under development for diverse indications. However, various safety concerns are associated with the mRNA platform. This Review discusses key challenges and toxicities identified during the development of mRNA drugs and vaccines, assesses models and tools used to limit toxicity, highlighting knowledge gaps and future directions.

Dimitrios Bitounis, Eric Jacquinet, Mansoor M. Amiji

Abstract

mRNA formulated with lipid nanoparticles is a transformative technology that has enabled the rapid development and administration of billions of coronavirus disease 2019 (COVID-19) vaccine doses worldwide. However, avoiding unacceptable toxicity with mRNA drugs and vaccines presents challenges. Lipid nanoparticle structural components, production methods, route of administration and proteins produced from complexed mRNAs all present toxicity concerns. Here, we discuss these concerns, specifically how cell tropism and tissue distribution of mRNA and lipid nanoparticles can lead to toxicity, and their possible reactogenicity. We focus on adverse events from mRNA applications for protein replacement and gene editing therapies as well as vaccines, tracing common biochemical and cellular pathways. The potential and limitations of existing models and tools used to screen for on-target efficacy and de-risk off-target toxicity, including in vivo and next-generation in vitro models, are also discussed.

Nature Reviews Genetics

Volume 25 Issue 4, April 2024

<https://www.nature.com/nrg/volumes/25/issues/4>

Perspective 13 Dec 2023

The transition from genomics to phenomics in personalized population health

This Perspective reviews large-scale genomics and longitudinal phenomics efforts and the insights they can provide into wellness. The authors describe their vision for the transformation of the current health care from disease-oriented to data-driven, wellness-oriented and personalized population health.

James T. Yurkovich, Simon J. Evans, Leroy E. Hood

Abstract

Modern health care faces several serious challenges, including an ageing population and its inherent burden of chronic diseases, rising costs and marginal quality metrics. By assessing and optimizing the health trajectory of each individual using a data-driven personalized approach that reflects their genetics, behaviour and environment, we can start to address these challenges. This assessment includes longitudinal phenome measures, such as the blood proteome and metabolome, gut microbiome composition and function, and lifestyle and behaviour through wearables and questionnaires. Here, we review ongoing large-scale genomics and longitudinal phenomics efforts and the powerful insights they provide into wellness. We describe our vision for the transformation

of the current health care from disease-oriented to data-driven, wellness-oriented and personalized population health.

Nature Reviews Immunology

Volume 24 Issue 4, April 2024

<https://www.nature.com/nri/volumes/24/issues/4>

Review Article 28 Sept 2023

[Immunological factors linked to geographical variation in vaccine responses](#)

The protective effect of vaccines is often poorest in low-income countries. Here, the authors explore the immunological factors that may explain the geographical variation in vaccine responsiveness and the ways in which they might be modulated to ensure effective vaccination in regions where it is needed most.

Marloes M. A. R. van Dorst, Jeremia J. Pyuza, Maria Yazdanbakhsh

Abstract

Vaccination is one of medicine's greatest achievements; however, its full potential is hampered by considerable variation in efficacy across populations and geographical regions. For example, attenuated malaria vaccines in high-income countries confer almost 100% protection, whereas in low-income regions these same vaccines achieve only 20–50% protection. This trend is also observed for other vaccines, such as bacillus Calmette–Guérin (BCG), rotavirus and yellow fever vaccines, in terms of either immunogenicity or efficacy. Multiple environmental factors affect vaccine responses, including pathogen exposure, microbiota composition and dietary nutrients. However, there has been variable success with interventions that target these individual factors, highlighting the need for a better understanding of their downstream immunological mechanisms to develop new ways of modulating vaccine responses. Here, we review the immunological factors that underlie geographical variation in vaccine responses. Through the identification of causal pathways that link environmental influences to vaccine responsiveness, it might become possible to devise modulatory compounds that can complement vaccines for better outcomes in regions where they are needed most.

New England Journal of Medicine

Volume 390 No. 15 April 18, 2024

<https://www.nejm.org/toc/nejm/medical-journal>

Perspectives

[Fundamentals of Medical Ethics: Expanding Applications of Clinical Genetic Testing — Ethical Challenges](#)

S.M. Fullerton and K.B. Brothers

NEJM Evidence

Volume 3 No. 4 April 2024

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 20 Apr 2024]

[No new digest content identified]

Pediatrics

Volume 153, Issue 4 April 2024

<https://publications.aap.org/pediatrics/issue/153/4>

[Reviewed earlier]

PharmacoEconomics

Volume 42, Issue 4 April 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-4>

[New issue; No digest content identified]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 20 Apr 2024)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 20 Apr 2024)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 20 Apr 2024)

[Uptake of Human Papilloma Virus vaccine among young women living in fishing communities in Wakiso and Mukono districts, Uganda](#)

Muteebwa Laban, Gertrude Nanyonjo, Mathias Wambuzi, Ali Ssetaala, Geoffrey Basalirwa, Dan Muramuzi, Jacqueline Kyosiimire Lujemwa, Brenda Okech, Ali Mirzazadeh

Research Article | published 18 Apr 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003106>

[Attitudes towards COVID-19 vaccination: A cross sectional study in the Federal Capital Territory, Nigeria](#)

Obi Peter Adigwe, Godspower Onavbavba

Research Article | published 18 Apr 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002589>

[Eliminating malaria in our time](#)

Caroline A. Lynch, Karma Lhazeen, Manash Shrestha, Varunika Ruwanpura, Neena Valecha, Kamala Thriemer

Opinion | published 17 Apr 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003086>

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 20 Apr 2024)

[Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the US COVID-19 scenario modeling hub](#)

Sung-mok Jung, Sara L. Loo, Emily Howerton, Lucie Contamin, Claire P. Smith, Erica C. Carcelén, Katie Yan, Samantha J. Bents, John Levander, Jessi Espino, Joseph C. Lemaitre, Koji Sato, Clifton D. McKee, Alison L. Hill, Matteo Chinazzi, Jessica T. Davis, Kunpeng Mu, Alessandro Vespignani, Erik T. Rosenstrom, Sebastian A. Rodriguez-Cartes, Julie S. Ivy, Maria E. Mayorga, Julie L. Swann, Guido España, Sean Cavany, Sean M. Moore, T. Alex Perkins, Shi Chen, Rajib Paul, Daniel Janies, Jean-Claude Thill, Ajitesh Srivastava, Majd Al Aawar, Kaiming Bi, Shraddha Ramdas Bandekar, Anass Bouchnita, Spencer J. Fox, Lauren Ancel Meyers, Przemyslaw Porebski, Srin Venkatramanan, Aniruddha Adiga, Benjamin Hurt, Brian Klahn, Joseph Outten, Jiangzhuo Chen, Henning Mortveit, Amanda Wilson, Stefan Hoops, Parantapa Bhattacharya, Dustin Machi, Anil Vullikanti, Bryan Lewis, Madhav Marathe, Harry Hochheiser, Michael C. Runge, Katriona Shea, Shaun Truelove, Cécile Viboud, Justin Lessler

Research Article | published 17 Apr 2024 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1004387>

This is an uncorrected proof.

Abstract

Background

Coronavirus Disease 2019 (COVID-19) continues to cause significant hospitalizations and deaths in the United States. Its continued burden and the impact of annually reformulated vaccines remain unclear. Here, we present projections of COVID-19 hospitalizations and deaths in the United States for the next 2 years under 2 plausible assumptions about immune escape (20% per year and 50% per year) and 3 possible CDC recommendations for the use of annually reformulated vaccines (no recommendation, vaccination for those aged 65 years and over, vaccination for all eligible age groups based on FDA approval).

Methods and findings

The COVID-19 Scenario Modeling Hub solicited projections of COVID-19 hospitalization and deaths between April 15, 2023 and April 15, 2025 under 6 scenarios representing the intersection of considered levels of immune escape and vaccination. Annually reformulated vaccines are assumed to be 65% effective against symptomatic infection with strains circulating on June 15 of each year and to become available on September 1. Age- and state-specific coverage in recommended groups was assumed to match that seen for the first (fall 2021) COVID-19 booster. State and national projections from 8 modeling teams were ensembled to produce projections for each scenario and expected reductions in disease outcomes due to vaccination over the projection period.

From April 15, 2023 to April 15, 2025, COVID-19 is projected to cause annual epidemics peaking November to January. In the most pessimistic scenario (high immune escape, no vaccination recommendation), we project 2.1 million (90% projection interval (PI) [1,438,000, 4,270,000]) hospitalizations and 209,000 (90% PI [139,000, 461,000]) deaths, exceeding pre-pandemic mortality of influenza and pneumonia. In high immune escape scenarios, vaccination of those aged 65+ results in 230,000 (95% confidence interval (CI) [104,000, 355,000]) fewer hospitalizations and 33,000 (95% CI [12,000, 54,000]) fewer deaths, while vaccination of all eligible individuals results in 431,000 (95% CI: 264,000–598,000) fewer hospitalizations and 49,000 (95% CI [29,000, 69,000]) fewer deaths.

Conclusions

COVID-19 is projected to be a significant public health threat over the coming 2 years. Broad vaccination has the potential to substantially reduce the burden of this disease, saving tens of thousands of lives each year.

PLOS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 20 Apr 2024)
[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 20 Apr 2024]

[Facilitators and barriers to vaccination uptake in pregnancy: A qualitative systematic review](#)

Mohammad S. Razai, Rania Mansour, Pahalavi Ravindran, Samuel Freeman, Charlotte Mason-Apps, Joan Morris, Azeem Majeed, Michael Ussher, Sally Hargreaves, Pippa Oakeshott

Research Article | published 19 Apr 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0298407>

[Pneumococcal vaccination and primary care presentations for acute respiratory tract infection and antibiotic prescribing in older adults](#)

Fariha Binte Hossain, Sanjay Jayasinghe, Katrina Blazek, Wen-Qiang He, Bette Liu

Research Article | published 18 Apr 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0299924>

[COVID-19 vaccine hesitancy among adults in Liberia, April–May 2021](#)

Lily M. Sanvee-Blebo, Peter A. Adewuyi, Faith K. Whesseh, Obafemi Joseph Babalola, Himiede W. Wilson-Sesay, Godwin E. Akpan, Chukwuma David Umeokonkwo, Peter Clement, Maame Amo-Addae

Research Article | published 17 Apr 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0297089>

[Research ethics review during the COVID-19 pandemic: An international study](#)

Fabio Salamanca-Buentello, Rachel Katz, Diego S. Silva, Ross E. G. Upshur, Maxwell J. Smith

Research Article | published 16 Apr 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0292512>

Abstract

Research ethics review committees (ERCs) worldwide faced daunting challenges during the COVID-19 pandemic. There was a need to balance rapid turnaround with rigorous evaluation of high-risk research protocols in the context of considerable uncertainty. This study explored the experiences and performance of ERCs during the pandemic. We conducted an anonymous, cross-sectional, global online survey of chairs (or their delegates) of ERCs who were involved in the review of COVID-19-related research protocols after March 2020. The survey ran from October 2022 to February 2023 and consisted of 50 items, with opportunities for descriptive responses to open-ended questions. Two hundred and three participants [130 from high-income countries (HICs) and 73 from low- and middle-income countries (LMICs)] completed our survey. Respondents came from diverse entities and organizations from 48 countries (19 HICs and 29 LMICs) in all World Health Organization regions. Responses show little of the increased global funding for COVID-19 research was allotted to the operation of ERCs. Few ERCs had pre-existing internal policies to address operation during public health emergencies, but almost half used existing guidelines. Most ERCs modified existing procedures or designed and implemented new ones but had not evaluated the success of these changes. Participants overwhelmingly endorsed permanently implementing several of them. Few ERCs added new members but non-member experts were consulted; quorum was generally achieved. Collaboration among ERCs was infrequent, but reviews conducted by external ERCs were recognized and validated. Review volume increased during the pandemic, with COVID-19-related studies being prioritized. Most protocol reviews were reported as taking less than three weeks. One-third of respondents reported external pressure on their ERCs from different

stakeholders to approve or reject specific COVID-19-related protocols. ERC members faced significant challenges to keep their committees functioning during the pandemic. Our findings can inform ERC approaches towards future public health emergencies. To our knowledge, this is the first international, COVID-19-related study of its kind.

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 20 Apr 2024]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

April 16, 2024 vol. 121 no. 16

<https://www.pnas.org/toc/pnas/121/16>

[New issue; No digest content identified]

PNAS Nexus

Volume 3, Issue 3, March 2024

<https://academic.oup.com/pnasnexus/issue/3/3>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 1 - February 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 180 March 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/180/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

10 April 2024 Volume 291 Issue 2020

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 228 Pages e1-e4, 1-206 (March 2024)

<https://www.sciencedirect.com/journal/public-health/vol/228/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 16, Issue 3, November 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 2, March/April 2024

<https://journals.sagepub.com/toc/phrg/139/2>

[Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 5, April 2024

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 20 Issue 2, April 2024

<http://journals.sagepub.com/toc/reab/current>

Special collection: Research Integrity and Research Misconduct

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 20 Apr 2024]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

[No new digest content identified]

Risk Analysis

Volume 44, Issue 3 Pages: 509-737 March 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 20 Apr 2024]

[Reviewed earlier]

Science

Volume 384| Issue 6693| 19 Apr 2024
<https://www.science.org/toc/science/current>
Editorial

[France needs a chief science adviser](#)

BY Patrick Lemaire, François Massol
18 Apr 2024

France is at a crossroads, facing environmental and social challenges that are profoundly altering its society. Yet, the French government keeps prioritizing short-term political gains over long-term evidence-based planning for major transitions that France, like most countries, will undergo over the next 20 years. There is an urgent need for France to implement long-term science-informed policy-making.

In Depth

[Plans to expand African vaccine production face steep hurdles](#)

BY Jon Cohen
18 Apr 2024: 254-255

Moderna's pause on Kenya project highlights difficulties in creating a competitive vaccine sector on the continent

Policy Forum

[Developing transmissible vaccines for animal infections](#)

BY Daniel G. Streicker [...] Scott L. Nuismer
18 Apr 2024: 275-277

Intrinsically safe designs and a staged transparent development process will be essential
Abstract

Many emerging and reemerging pathogens originate from wildlife, but nearly all wild species are unreachable using conventional vaccination, which requires capture of and vaccine administration to individual animals. By enabling immunization at scales sufficient to interrupt pathogen transmission, transmissible vaccines (TVs) that spread themselves through wildlife populations by infectious processes could potentially transform the management of otherwise intractable challenges to public health, wildlife conservation, and animal welfare. However, generating TVs likely requires modifying viruses that would be intended to spread in nature, which raises concerns ranging from technical feasibility, to safety and security risks, to regulatory uncertainties (1, 2). We propose a series of commitments and strategies for vaccine development—beginning with a priori decisions on vaccine design and continuing through to stakeholder codevelopment [see supplementary materials (SM)]—that we believe increase the likelihood that the potential risks of vaccine transmission are outweighed by benefits to conservation, animal welfare, and zoonosis prevention.

Science and Engineering Ethics

Volume 30, Issue 2 April 2024
<https://link.springer.com/journal/11948/volumes-and-issues/30-2>
[Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 743| 17 Apr 2024
<https://www.science.org/toc/stm/current>
[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 20 Apr 2024]

[No new digest content identified]

Social Science & Medicine

Volume 346 April 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/346/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 20 Apr 2024]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 2 April 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-2>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 58 March–April 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/58/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 29, Issue 4 Pages: i-iv, 257-342 April 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[New issue; No digest content identified]

Vaccine

Volume 42, Issue 10 Pages 2495-2728 (11 April 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/10>

Commentaries

Discussion Abstract only

[Rabies vaccination of the Maxakali indigenous population](#)

Dilceu Silveira Tolentino Júnior, Maryana Santos Vasconcelos Marques, Roberto Carlos de Oliveira

Pages 2495-2498

Highlights

- :: Overview of the mass rabies vaccination carried out in an indigenous Brazilian population.
- :: Technical, operational and logistical adaptations adapted to the local demographic reality.
- :: The benefits of vaccination in response to a rabies outbreak outweigh the risks.
- :: Only serological control will determine the effectiveness of mass rabies vaccination.

Research article *Open access*

[Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial](#)

Dorota Borys, Richard Rupp, Ronald Smulders, Gurunadh R. Chichili, ... Shite Sebastian
Pages 2560-2571

Research article Open access

[The effect of a financial incentive on COVID-19 vaccination uptake, and predictors of uptake, in people experiencing homelessness: A randomized controlled trial](#)

Laura K. McCosker, Robert S. Ware, Holly Seale, Dona Hooshmand, ... Martin J. Downes
Pages 2578-2584

Research article Abstract only

[Do boys have the same intentions to get the HPV vaccine as girls? Knowledge, attitudes, and intentions in France](#)

Catherine Juneau, Estelle Fall, Julie Bros, Anne-Sophie Le Duc-Banaszuk, ... Aurélie Gauchet
Pages 2628-2636

Research article Abstract only

[Measles vaccination coverage and immunization status of nurses: An interventional study in Türkiye](#)

Volkan Medeni, Özge Tonbuluğlu Altınır, İrem Medeni
Pages 2716-2721

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 20 Apr 2024]

Open Access Article

[Using a Dynamic Model to Estimate the Cost-Effectiveness of HPV Vaccination in Iran](#)

by Arnold Hagens, Albertus Constantijn Sloof and Roksana Janghorban

Vaccines 2024, 12(4), 438; <https://doi.org/10.3390/vaccines12040438> - 18 Apr 2024

Abstract

This study aimed to determine the cost-effectiveness of vaccination against HPV. An age–sex structured dynamic disease transmission model was created to estimate the spread of HPV and the HPV-related incidence of cervical cancer (CC) in Iran. Sixteen age groups of men and women

Open Access Article

[Comparison of Wealth-Related Inequality in Tetanus Vaccination Coverage before and during Pregnancy: A Cross-Sectional Analysis of 72 Low- and Middle-Income Countries](#)

by Nicole E. Johns, Cauane Blumenberg, Katherine Kirkby, Adrien Allorant, Francine Dos Santos Costa, M. Carolina Danovaro-Holliday, Carrie Lyons, Nasir Yusuf, Aluísio J. D. Barros and Ahmad Reza Hosseinpoor

Vaccines 2024, 12(4), 431; <https://doi.org/10.3390/vaccines12040431> - 17 Apr 2024

Abstract

Immunization of pregnant women against tetanus is a key strategy for reducing tetanus morbidity and mortality while also achieving the goal of maternal and neonatal tetanus elimination. Despite substantial progress in improving newborn protection from tetanus at birth through maternal immunization, umbilical cord

Value in Health

April 2024 Volume 27 Issue 4 p383-542

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 176 April 2024

<https://www.sciencedirect.com/journal/world-development/vol/176/suppl/C>

[Reviewed earlier]



Contents *[click to move among sections]*

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)



Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 20 Apr 2024]

Selected Research

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 20 Apr 2024]

[Filter: All articles]

[Factors Associated with Non-and Incomplete Vaccination Among Children Aged 12-23 Months in Gindhir Rural District, Southeast Ethiopia: A Multinomial Analysis](#)

Geremew Tsegaye Mulugeta, Desta Hiko Gemedra, Abraham Lomboro Dimore, Tihitina Yohhanes Getu, Adamu Gelaw Zerihun, Adane Woldeab Doyamo

medRxiv 2024.04.19.24306059; doi: <https://doi.org/10.1101/2024.04.19.24306059>

[Evaluating the effectiveness of the HPV vaccination programme in England, using regression discontinuity design](#)

Isobel L. Ward, Charlotte Bermingham, Kate Soldan, Vahe Nafilyan

medRxiv 2024.04.19.24306076; doi: <https://doi.org/10.1101/2024.04.19.24306076>

[High measles and rubella vaccine coverage and seroprevalence among Zambian children participating in a measles and rubella supplementary immunization activity](#)

Christine Prospero, Shaun Truelove, Andrea C Carcelen, Gershom Chongwe, Francis D Mwansa, Phillimon Ndubani, Edgar Simulundu, Innocent C Bwalya, Mutinta Hamahuwa, Kelvin Kapungu, Kalumbu H Matakala, Gloria Musukwa, Irene Mutale, Evans Betha, Nchimunya Chaavwa, Lombe Kampamba, Japhet Matoba, Passwell Munachoonga, Webster Mufwambi, Ken Situtu, Philip E Thuma, Constance Sakala, Princess Kayeye, Amy K. Winter, Matthew J Ferrari, William J Moss, Simon Mutembo

medRxiv 2024.04.18.24306051; doi: <https://doi.org/10.1101/2024.04.18.24306051>

[Projecting international mpox spread in Asia: ongoing global health risk](#)

Toshiaki R. Asakura, Sung-mok Jung, Hiroaki Murayama, Cyrus Ghaznavi, Haruka Sakamoto, Ayaka Teshima, Fuminari Miura, Akira Endo

medRxiv 2024.04.17.24305832; doi: <https://doi.org/10.1101/2024.04.17.24305832>

[Vaccine preparation time, errors, satisfaction, and preference of prefilled syringes versus RSV vaccines requiring reconstitution: randomized, time and motion study](#)

Darshan Mehta, Samantha Kimball-Carroll, Dayna R. Clark, Serena Fossati, Matthias Hunger, Ankit Pahwa, Mia Malmenas, Brian Hille, Nicolas Van de Velde

medRxiv 2024.04.16.24305921; doi: <https://doi.org/10.1101/2024.04.16.24305921>

[Long-term waning of vaccine-induced immunity to measles in England](#)

Alexis Robert, Anne M Suffel, Adam J Kucharski

medRxiv 2024.04.18.24306028; doi: <https://doi.org/10.1101/2024.04.18.24306028>

[Prevalence of physical and mental health problems among internally displaced persons in white Nile state, Sudan 2023](#)

Ahmed Mohamed Ahmed Ali, Omran aldoma Mohammed Adam, Sarah Altayeb Mustafa Salem, Sara Hamad Ibrahim Hamad, Nosiba Elnair Musa Ahmed, Hassan Mohamed Ahmed Ali, Aseel Abass Mohamed Abass, Hiba-Allah Abass Mohamed Abass, Abubaker Izz-Eldein Albasher, Mawada Eltagi Elsayid Yousif, Fadwa Elfadil Ahmed Abdalla, Osman AlShazly Osman Abd-alaziz, Samar Bushra Mohammed Ahmed, Shaima Abdelbagi Ahmed Al-Obaid, Abdelgadir H. Osman

medRxiv 2024.04.16.24305844; doi: <https://doi.org/10.1101/2024.04.16.24305844>

[Resources to Aid Ethical Review of Clinical Studies: An Exploratory Scoping Review Identifying Gaps and Opportunities](#)

Merle-Marie Pittelkow, Daniel Strech

medRxiv 2023.12.13.23299842; doi: <https://doi.org/10.1101/2023.12.13.23299842> Revision

[Vaccination as personal public-good provision](#)

J. Lucas Reddinger, Gary Charness, David Levine

medRxiv 2022.04.21.22274110; doi: <https://doi.org/10.1101/2022.04.21.22274110> Revision

[Bangladesh should engage the private sector for malaria elimination by 2030](#)

Ryan Patrick McArdle, Ching Swe Phru, Mohammad Sharif Hossain, Mohammad Shafiul Alam, Kasturi Haldar

medRxiv 2024.04.10.24305490; doi: <https://doi.org/10.1101/2024.04.10.24305490>

[Deaths averted by COVID-19 vaccination in select Latin American and Caribbean Countries: a modelling study](#)

Alexandra Savinkina, Daniel M. Weinberger, Cristiana M. Toscano, Lucia H. De Oliveira

medRxiv 2024.04.12.24305739; doi: <https://doi.org/10.1101/2024.04.12.24305739>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[Reporting of cluster randomised crossover trials 2023: extension of the CONSORT 2010 statement with explanation and elaboration](#)

Authors

Joanne McKenzie, Monica Taljaard, Karla Hemming, Sarah Arnup, Bruno Giraudeau, Sandra Eldridge, Richard Hooper, Brennan Kahan, Tianjing Li, David Moher, ...

Abstract

In this report we present the Consolidated Standards of Reporting Trials (CONSORT) extension for the cluster randomised crossover (CRXO) trial. A CRXO trial involves randomisation of groups of individuals ('clusters') to different sequences of treatments over time. The design has gained popularity in settings where cluster randomisation is required as it can largely overcome the loss in power due to clustering in parallel cluster trials. However, the design has many methodological complexities, requiring tailored reporting guidance. The guideline was developed using a survey and in-person consensus meeting, informed by a systematic review examining the quality of reporting in CRXO trials and relevant CONSORT statements for individual, crossover, cluster and stepped-wedge designs. We provide recommended reporting items, along with explanations and examples.

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 20 Apr 2024]

Selected Research

Research Article Open Access

[Human placental cells are resistant to SARS-CoV-2 infection and replication](#)

[version 1; peer review: awaiting peer review]

Nagisa Yoshida, et al.

Abstract

Background

Infection during pregnancy with SARS-CoV-2 can have a serious impact on both maternal and foetal health. Clinical studies have shown that SARS-CoV-2 transmission from the mother to the foetus typically does not occur. However, there is evidence that SARS-CoV-2 can infect the placenta in utero. Here we sought to quantify the permissiveness of placental cells to SARS-CoV-2 infection and to determine if they support viral release... The low level of viral release by primary placental cells provides insight into how the virus is impaired from crossing the placenta to the foetus.

Review Open Access

[Ethics and health research priority setting: a narrative review](#)

[version 1; peer review: awaiting peer review]

Joseph Millum, Philosophy, University of St Andrews, St Andrews, Scotland, KY16 9AL, UK

Abstract

This narrative review aims to describe current practice and ongoing discussions in the academic literature regarding ethics and health research priority setting. It begins with some preliminary distinctions regarding types of research priority setting. It then gives some background on current practice with respect to formal research priority setting exercises, including summaries of The Ad Hoc Committee on Health Research method, the Child Health and Nutrition Research Initiative (CHNRI) method, the Combined Approach Matrix (CAM), the Delphi method, the Essential National Health Research (ENHR) strategy for priority setting, and the James Lind Alliance (JLA) framework. The majority of the paper reports the results of a literature review covering specifically ethical issues under the thematic headings of process criteria, substantive criteria, global justice, the obligations of specific actors, and research topics. It closes with some summary thoughts about apparent gaps and directions for future investigation.

Plain language summary

More health research is needed to develop new treatment and prevention options for many diseases. But there are limited resources available to support health research. This means that difficult decisions must be made about how to allocate those resources among competing important

projects. Making these decisions is called priority setting. Dr. Joseph Millum reviewed what has been published on the ethics of health research priority setting. First, he compared different methods that have already been developed to help organizations and governments set priorities. Second, he identified themes in the current discussions about ethics and priority setting. Some important themes included: how stakeholders should be included in priority setting exercises; what would be a fair allocation of research resources; global disparities in health research; and how different types of funder should think about their obligations. The results of this review will inform guidance from the World Health Organization on how to incorporate ethics into health research priority setting.

* * * *

Think Tanks

Brookings [to 20 Apr 2024]

<http://www.brookings.edu/>

Research

No new digest content identified.

Center for Global Development [to 20 Apr 2024]

<https://www.cgdev.org/>

All Research [Selected]

POLICY PAPERS

[Disinvesting from Low-Value Health Technologies in Low- and Middle-Income Countries: Between a Solution to the Current Fiscal Crises and a Costly Mirage?](#)

Adrian Gheorghe and Peter Baker

April 15, 2024

Many low- and middle-income countries are projected to spend less on health over the rest of this decade than they did pre-2020. The adage “more health for the money” is more meaningful than ever—but how do we act on it quickly? Disinvesting from low-value health technologies and interventions is on...

Chatham House [to 20 Apr 2024]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 20 Apr 2024]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 20 Apr 2024]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 20 Apr 2024]
https://www.kff.org/search/?post_type=press-release
Newsroom
No new digest content identified.

McKinsey Global Institute [to 20 Apr 2024]
<https://www.mckinsey.com/mgi/overview>
Latest Research
No new digest content identified.

ODI [Overseas Development Institute] [to 20 Apr 2024]
<https://odi.org/en/publications/>
Publications [Selected]
No new digest content identified.

Pew Research Center [to 20 Apr 2024]
<https://www.pewresearch.org/>
Latest Publications [Selected]
No new digest content identified.

Rand [to 20 Apr 2024]
<https://www.rand.org/pubs.html>
Published Research [Selected]
No new digest content identified.

Urban Institute [to 20 Apr 2024]
<https://www.urban.org/publications>
[New Research Publications - Selected](#)

World Economic Forum [to 20 Apr 2024]
<https://agenda.weforum.org/press/>
Media [Selected]
No new digest content identified.

.....
.....

Public Consultations/Call for Inputs/Call for Papers
Invitation for Public Comment: WHO principles for human genome access, use and sharing

8 April 2024 **Consultation Period: 8th April 2024 – 3 May 2024**

Background:

For the potential of genomics to be realized, access to, use, and the sharing of human genome data is critical. Following the WHO's Science Council 2022 Report on Accelerating access to genomics for global health: promotion, implementation, collaboration, and ethical, legal, and social

issues, WHO is implementing a programme of activities to promote equitable and fair access to genomics technologies for the benefit of people worldwide. As part of this, WHO is developing guiding principles for human genome data access, use and sharing. To develop these principles, a virtual consultation was held in January 2024 with an interdisciplinary group of participants. This consultation discussed the diverse perspectives on issues related to human genome data access, use and sharing; how a global set of principles from WHO may enable data access, use and sharing; and proposed initial principles. This was followed by an in-person meeting in March 2024 that considered in detail the proposed principles. Following this meeting, a draft document was developed and comments on this document and the principles are now invited.

Feedback on the WHO Principles for human genome data access, use, and sharing Public feedback on this document is being solicited through this public consultation using the [comment form](#).

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*
*

*
*

*
*

*
*